Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini Genenta (Nasdaq: GNTA) announced on March 24, 2026 that it is evolving into Saentra Forge, an industrial consolidator targeting biotech, defense, aerospace and national-security technologies. The company said it is working with DC Advisory to explore collaboration opportunities for its original biotechnology platform, but has no active discussions regarding Temferon to date.Management emphasized continued pursuit of partners given prior preliminary clinical data, founder-scientists' ongoing shareholdings, and a strategic shift toward selective acquisitions and industrial aggregation.

#GNTA Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini

www.stocktitan.net/news/GNTA/genenta-evolvi...

Genenta, Evolving into Saentra Forge, Announces CEO’s Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University Genenta (Nasdaq: GNTA), evolving to Saentra Forge (Nasdaq: SAEN), announced on March 13, 2026 that CEO Pierluigi Paracchi was appointed by the Italian government to the Board of Guarantors of the Italian Academy at Columbia University.The appointment, conferred by Deputy Prime Minister Antonio Tajani and transmitted by Ambassador Marco Peronaci, places the CEO on a 12‑member board that supports the Academy’s research and cultural exchange activities.

#GNTA Genenta, Evolving into Saentra Forge, Announces CEO’s Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University

www.stocktitan.net/news/GNTA/genenta-evolvi...

Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian Companies ATC - a Defense-Sector Company: First Industrial Integration Praexidia Foundation Joins as a Long-Term Strategic Shareholder Corporate Name

#GNTA Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator

www.stocktitan.net/news/GNTA/genenta-announ...

Genenta Science Provides Update on CEO Ownership Genenta Science (Nasdaq: GNTA) updated ownership details for CEO and co-founder Pierluigi Paracchi as of December 19, 2025. The company reports Mr. Paracchi has acquired 30,000 ADSs over time via open-market purchases and has not reported any sales in SEC filings. In total, he owns 2,326,129 ADSs and ordinary shares, representing approximately 10% of Genenta’s outstanding share capital as calculated under SEC rules.The disclosure indicates founder insider accumulation and a sizable single-holder stake that investors may consider when evaluating free float and insider alignment.

#GNTA Genenta Science Provides Update on CEO Ownership

www.stocktitan.net/news/GNTA/genenta-scienc...

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial Genenta Science (Nasdaq: GNTA) reported a November 21, 2025 data cut from its TEM-GBM study in newly diagnosed glioblastoma patients with unmethylated MGMT. As of the cut, 25 patients treated with Temferon showed 44% 18‑month survival (vs 38% in April), a 2‑year survival of 29%, and median overall survival of 17 months, all consistent with prior updates. Historical uMGMT benchmarks cited: ~14% two‑year survival and 13–15 months median OS. One patient reached 39 months post‑surgery without intervening therapy and completed a 3.5‑year follow‑up. Findings include preliminary immune evidence that bone‑marrow‑derived myeloid cells can reach tumor tissue to deliver payloads. The company held approximately $30 million in cash and short‑term investments as of November 1, 2025.

#GNTA Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

www.stocktitan.net/news/GNTA/genenta-report...

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares Genenta Science (Nasdaq: GNTA) announced a registered direct offering to sell 4,285,715 ADSs at $3.50 per ADS for gross proceeds of approximately $15.0 million, before fees and expenses. Maxim Group is lead placement agent and Rodman & Renshaw is co-placement agent. Genenta intends to use net proceeds for working capital and general corporate purposes. The offering is expected to close on or about October 28, 2025, subject to customary closing conditions and a prospectus supplement to be filed under its effective Form F-3 registration.

#GNTA Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

www.stocktitan.net/news/GNTA/genenta-announ...

Nasdaq Surges 1%; Procter & Gamble Posts Upbeat Earnings - Genenta Science (NASDAQ:GNTA), Datavault AI (NASDAQ:DVLT)

Nasdaq Surges 1%; Procter & Gamble Posts Upbeat Earnings read more

#DVLT #Earnings #GNTA #Mid #Morning #Market #Update #MSAI #NEUP #News #PG

Origin | Interest | Match

Just In: ( NASDAQ: #GNTA ) Next Entertainment Boom Ignited, Blowout Earnings, Bio Science, and Merger News, as Wall Street Turns Up the Volume

📢 Stocks Trending NOW: #INTC #PG #DECK #SCNX #WGRX #GNTA #QLGN #VIVK #ITGR #GD

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production Genenta Science (Nasdaq: GNTA) and ANEMOCYTE announced an expanded strategic collaboration on an off-the-shelf lentiviral vector (LVV) Plasmid DNA technology platform, dated October 24, 2025. The agreement builds on an existing partnership and makes Genenta's clinically validated LVV Plasmid DNA platform, originating from research by Professor Luigi Naldini, available to ANEMOCYTE and its clients.The collaboration aims to supply top-quality plasmid DNA across R&D to GMP grade and from preclinical to commercial stages, supporting scalable advanced therapy program development and broadening ANEMOCYTE's offering to customers.

#GNTA Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

www.stocktitan.net/news/GNTA/genenta-and-an...

Who is Thami Moyo? Gauteng Taxi Leader Shot Dead in Soweto Highway Attack Thami Moyo death has shocked South Africa. The GNTA chairperson was shot dead on Soweto Highway in a case linked to Gauteng taxi violence. Santaco leaders, Transport Minister Barbara Creecy, and polic...

Who is Thami Moyo? Gauteng Taxi Leader Shot Dead in Soweto Highway Attack
#ThamiMoyo #GNTA #Santaco #TaxiViolence #Gauteng #SowetoHighway #SouthAfricaNews #BreakingNews #Transport
gtvnewshd.com/biography/20...

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that a total of 38 patients were enrolled in newly diagnosed glioblastoma multiforme (TEM-GBM)

#GNTA Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

www.stocktitan.net/news/GNTA/genenta-announ...

"Mit der Stringenz einer Jurorin für »Germany’s Next Top-Abgeordnete« führt sie durch ihre ersten Wochen im zweithöchsten Staatsamt, stets auf der Suche nach neuen Stilverbrechen im Parlament (...)"

Ich liebe @samelou.bsky.social 😊

🎁-Link by @sachlichepolitik.bsky.social

#Klöckner #GNTA

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies Genenta Science (GNTA) has announced a strategic collaboration with Anemocyte, an Italian Biotech Manufacturing Organization (BMO), for the production of critical starting materials for cell-based therapies. The partnership involves the successful establishment of Cell Banks and manufacturing of Plasmids for viral vector production. Anemocyte's expertise has been crucial in supporting Genenta's clinical trials progression through high-quality manufacturing processes. The collaboration highlights the synergy between Genenta's immuno-oncology platform and Anemocyte's manufacturing capabilities, with Genenta being notably recognized as the first Italian company listed on Nasdaq.

#GNTA Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

www.stocktitan.net/news/GNTA/genenta-and-an...

Genenta Lands €23M Strategic Investment: Major Qatar Expansion Plans Revealed Fresh €23M funding fuels Temferon cancer therapy advancement. Strategic presentation to Qatar's $475B sovereign fund signals global expansion potential.

#GNTA Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

www.stocktitan.net/news/GNTA/genenta-showca...

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates Genenta Science (GNTA) has secured a €20 million ($21.9M) financing through a Mandatory Convertible Bond from ENEA Tech and Biomedical (ETB) to expand its pipeline. The funding will support advancing Temferon in metastatic Renal Cell Cancer (mRCC).The bond structure includes a first tranche of €7.5M for safety assessment in the mRCC trial, and a second tranche of €12.5M conditional upon achieving safety milestones. The bond matures in March 2028 with a two-year lock-up period, and ETB's equity will be capped at 29% with a maximum conversion price of $17.64 per share.Recent data from the Phase 1/2a Glioblastoma Multiforme (GBM) uMGMT trial shows promising results with 29% patient survival at two years (up from 25% in October) and 17 months median overall survival, compared to historical data of 14% two-year survival and 13-15 months median survival with standard care.

#GNTA Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

www.stocktitan.net/news/GNTA/genenta-announ...

Italy Showcases €270B Life Sciences Hub at J.P. Morgan Healthcare Conference 2025 Five innovative Italian startups to present at "Italy on the Move" event in San Francisco, highlighting investment opportunities in biotech, healthcare, and medical devices.

#GNTA "Italy on the Move" returns during the J.P. Morgan Healthcare Conference 2025

www.stocktitan.net/news/GNTA/italy-on-the-m...

Genenta Science Secures Exclusive Manufacturing Suite for Breakthrough Cancer Cell Therapy Genenta enhances AGC Biologics partnership with dedicated GMP suite in Milan, accelerating production of Temferon for renal cancer and glioblastoma clinical trials.

#GNTA Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

www.stocktitan.net/news/GNTA/genenta-streng...

NEWS: ( NASDAQ: #GNTA ) ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

Just In: ( NASDAQ: #GNTA ) Genenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective"

#StockMarket #News

NEWS: ( NASDAQ: #GNTA ) Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

#StockMarket #News